Arca
Skip to content
Tools
Tools

Ischemia

Drug research and approvals for ischemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 18, 2026, 1,987 studies of ischemia are recruiting on ClinicalTrials.gov, Health Canada has authorized 2 drug trials for it since 2013, and FDA has 1 approved and 25 open orphan designations naming it.

  • Recruiting worldwide: 1,987
  • Trials authorized in Canada: 2
  • FDA orphan approvals: 1
  • EU medicines: 0

Recruiting now

Newest start dates first, of 1,987 recruiting on ClinicalTrials.gov ↗

Drug pipeline

1 approved, 6 in phase 3, 8 in phase 2, 8 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition

Approved: Clopidogrel

Aspirin
Phase 3 Cyclooxygenase inhibitor
Paclitaxel
Phase 3 Tubulin inhibitor
Apixaban
Phase 3 Coagulation factor X inhibitor
Cangrelor
Phase 3 Purinergic receptor P2Y12 antagonist
Emiplacel
Phase 3
Dexamethasone phosphoric acid
Phase 2 Glucocorticoid receptor agonist
Rivaroxaban
Phase 2 Coagulation factor X inhibitor
Temsirolimus
Phase 2 FK506-binding protein 1A inhibitor
Rosuvastatin
Phase 2 HMG-CoA reductase inhibitor
Moxaverine
Phase 2
Enalapril
Phase 1 Angiotensin-converting enzyme inhibitor
Ticagrelor
Phase 1 Purinergic receptor P2Y12 negative allosteric modulator
Adenosine
Phase 1 Adenosine receptor agonist
Acetylcholine
Phase 1 Muscarinic acetylcholine receptor M3 agonist
Oxygen
Phase 1 Essential for cellular homeostasis
Edetate disodium anhydrous
Early phase 1 Calcium chelating agent

How its trials ended

2,346 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 430 whose ending is known, 37% met their primary endpoint, 13% missed it and 50% stopped early.

  • Completed, result not reported83636%
  • Ongoing59125%
  • Status unknown48921%
  • Met its primary endpoint1607%
  • Stopped: other or unclear1215%
  • Missed its primary endpoint552%
  • Stopped: enrollment or feasibility512%
  • Stopped: sponsor or business decision201%
  • Stopped: lack of efficacy151%
  • Stopped: funding50%
  • Stopped: safety30%

Trials authorized in Canada

Newest first; search them all in Canada trials
Dec 20, 2018"evaluation of prognostic value of 18f-fluoroazomycin arabinoside (FAZA)18F-FLUOROAZOMYCIN arabinoside (FAZA)Centre for Probe Development and CommercializationOngoing
May 5, 2016Enhancing the anabolic effect of nutrition in critically ill patients by administering exogenous amino acidsAmino acidsResearch Institute of The McGill University Health CentrePending

FDA orphan designations

Approved first, then open designations, newest first; 15 of 26
Jun 25, 1992Lioresal IntrathecalManagement of severe spasticity of spinal cord origin in patients who are unresponsive to oral baclofen therapy or experience intolerable…Medtronic, Inc.Approved
Nov 6, 2023AlprostadilPrevention of ischemia/reperfusion injury resulting from solid organ transplantation.Institut Georges LopezDesignated
May 31, 2023N-myristoylated -Glu-Ala-Val-Ser-Leu-Lys-Pro-ThrPrevention of ischemia/reperfusion injury in kidney transplantationYoung Therapeutics, LLCDesignated
Dec 14, 2022Ketamine hydrochloridePrevention of ischemia/reperfusion injury during solid organ transplantation.PharmaTher Inc.Designated
Oct 17, 2022Synthetic polymer PEG conjugated to a phospholipid anchor…Prevention of ischemia reperfusion injury during solid organ transplantationiCoat Medical ABDesignated
Feb 15, 2022BucillaminePrevention of ischemia-reperfusion injury during liver transplantationRevive Therapeutics Inc.Designated
Apr 27, 2021DimethyltryptaminePrevention of ischemia-reperfusion injury in patients undergoing solid organ transplantation.Sairiyo Therapeutics Inc.Designated
Jul 10, 2020MitochondriaPrevention of ischemia-reperfusion injury during solid organ transplantationcellvie Inc.Designated
Nov 5, 2018CannabidiolPrevention of ischemia/reperfusion Injury resulting from solid organ transplantationRevive Therapeutics Ltd.Designated
Aug 3, 2017PapaverineTreatment of mesenteric ischemiaRNR BioMedical Inc.Designated
May 2, 2017Macromolecular conjugate of heparin sodium on a polymer…Prevention of ischemia-reperfusion injury associated with solid organ tranplantationCorline Biomedical ABDesignated
Dec 31, 2015Adeno-associated viral vector expressing the human vascular…Treatment of critical limb ischemia in no-option patients where other procedures, grafts, or angioplasty are not indicatedIntegene International Holding, LLCDesignated
Oct 16, 2014Cardiotrophin-1Prevention of ischemia-reperfusion injury in kidney transplant recipientsDigna Biotech, S.L.Designated
Nov 8, 2013Poloxamer 188Treatment of Acute Limb IschemiaMast Therapeutics Inc.Designated
Aug 6, 2013Human HeminPrevention of ischemia reperfusion injury in patients undergoing solid organ transplantationBorders Technology Management LtdDesignated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.